Is silence golden? A test of the incorporation of the effects of ill-health on income and leisure in health state valuations

Health Economics

Volumn 14, Issue 6, 2005, Pages 643-647

  Sendi, Pedram ^a   Brouwer, Werner B F ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Methodology; Productivity costs; Quality of life

Indexed keywords

ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH PRACTITIONER; HEALTH STATUS; HUMAN; INCOME; LEISURE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; STATISTICAL ANALYSIS; VISUAL ANALOG SCALE;

ADULT; ATTITUDE OF HEALTH PERSONNEL; COST OF ILLNESS; HEALTH STATUS; HUMANS; INCOME; LEISURE ACTIVITIES; MALE; MULTIPLE SCLEROSIS; PAIN MEASUREMENT; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES;

EID: 20444379575     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.971     Document Type: Article

References (12)

1. Sculpher M. The role and estimation of productivity costs in economic evaluation. In Drummond MF, McGuire A (eds), Economic Evaluation in Health Care: Merging Theory with Practice. Oxford University Press: Oxford, 2001; 94-112.
2. Rothermich EA, Pathak DS. Productivity-cost controversies in cost-effectiveness analysis: review and research agenda. Clin Ther 1999; 21: 255-267.
3. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. Oxford University Press: Oxford, 1996.
4. Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. Health Econ 1997; 6: 253-259.
5. Johannesson M. Avoiding double-counting in pharmacoeconomic studies. Pharmacoeconomics 1997; 11: 385-388.
6. Weinstein MC, Siegel JE, Garber AM et al. Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. Health Econ 1997; 6: 505-510.
7. Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ 1997; 6: 511-514.
8. Brouwer WB, Koopmanschap MA, Rutten FF. Patient and informal caregiver time in cost-effectiveness analysis. A response to the recommendations of the Washington Panel. Int J Technol Assess Health Care 1998; 14: 505-513.
9. Meltzer D, Johannesson M. Inconsistencies in the 'societal perspective' on costs of the Panel on cost-effectiveness in Health and Medicine. Med Decis Making 1999; 19: 371-377.
10. Sendi P, Brouwer WB. Leisure time in economic evaluation: theoretical and practical considerations. Expert Rev Pharmacoeconomics Outcomes Res 2004; 4: 1-4.
11. Meltzer DO, Weckerle CE, Chang LM. Do people consider financial effects in answering quality of life questions? Med Decis Making 1999; 19: 517.
12. Brouwer WB, Rutten FF. The missing link: on the line between C and E. Health Econ 2003; 12: 629-636.